01
Understand the Disease
Develop a deep understanding of the disease, the patient journey, current standards of care, and the unmet medical need. Commercial strategy begins with understanding the clinical environment.
Practice Areas
Launch Excellence
Building commercial success long before FDA approval—with plans grounded in decades of commercial leadership experience.
Executive Summary
Every biotechnology company begins with the same goal: to develop an innovative therapy that improves patients' lives. Yet only a small percentage of companies ever reach the point of launching a product independently. Some programs fail during clinical development. Others are acquired before commercialization or choose to partner with larger pharmaceutical companies rather than build a commercial organization.
For those that do commercialize independently, success is rarely determined during the final months before launch. It is shaped by decisions made years earlier.
Throughout more than thirty years leading commercial organizations in specialty pharmaceuticals, neuroscience, endocrinology, and rare disease, I have learned that successful commercialization rarely depends on one major decision. It is the result of hundreds of thoughtful decisions made consistently throughout development.
Commercialization is most successful when it becomes part of the development strategy—not something added near FDA approval.
Commercialization Begins Earlier Than Most Companies Realize
One of the most common mistakes I see is treating commercialization as something that begins shortly before FDA approval. By that point, many of the most important commercial decisions have already been made.
Clinical development and commercialization should evolve together. Decisions made during development influence physician confidence, payer acceptance, patient identification, manufacturing, distribution, and ultimately long-term commercial performance.
The strongest companies build commercial thinking into development from the beginning.
Know the Market You Are Actually Launching Into
Commercial forecasts are valuable, but they rarely reflect how healthcare functions in the real world.
Leadership teams should understand:
- How many patients are actually diagnosed.
- Where patients receive care.
- Which physicians influence treatment decisions.
- How patients move through the healthcare system.
- What barriers delay diagnosis or treatment.
- How competitors have performed under similar market conditions.
Realistic assumptions produce better commercial decisions than optimistic forecasts.
Market Access Cannot Be an Afterthought
One of the biggest misconceptions in biotechnology is that reimbursement begins after FDA approval.
In reality, payer expectations begin much earlier.
Commercial planning should include health economic evidence, budget impact analyses, specialty pharmacy strategy, patient support services, and practical approaches to prior authorization and reimbursement.
For many specialty and rare disease therapies, patient access—not physician interest—becomes the greatest commercial challenge.
Physician Confidence Is Earned
FDA approval creates availability.
It does not automatically create physician confidence.
Physicians want evidence that a therapy fits into everyday clinical practice, that reimbursement is achievable, and that patients can successfully begin treatment.
Confidence develops through scientific credibility, experienced Medical Affairs teams, respected investigators, Centers of Excellence, and meaningful clinical support—not promotional activity alone.
Leadership Decisions Shape Commercial Success
Outstanding products can struggle when commercial leadership lacks the experience or adaptability required for a successful launch.
The strongest leaders understand that every therapeutic area presents different scientific, operational, reimbursement, and organizational challenges.
Successful commercialization depends as much on leadership quality as it does on clinical data.
Launch Excellence in Rare Disease
Rare disease commercialization requires a different approach.
Patient populations are small and geographically dispersed. Diagnosis often takes years. Care is concentrated within a limited number of academic medical centers and Centers of Excellence, while many patients live far from those institutions. Complex prior authorization requirements and specialty pharmacy coordination frequently delay treatment.
Understanding these realities early allows organizations to develop practical commercial strategies that improve physician confidence and patient access.
Final Thoughts
Every biotechnology company hopes to reach commercial launch. Relatively few have the opportunity.
For those that do, success is rarely determined by a single event or one major decision. It comes from hundreds of thoughtful choices made throughout development—long before the first sales call or the first prescription.
Clinical innovation brings a therapy to approval.
Commercial excellence brings that therapy to patients.
That is where PharmaKonsult helps biotechnology companies make better commercial decisions.
Product Commercialization Strategy
The Eight Principles of Product Commercialization
An Executive Summary
A successful product launch begins long before FDA approval.
Commercialization is not a single event—it is a series of strategic decisions that determine whether an innovative therapy can successfully reach patients while creating long-term value for the company.
Over more than 30 years in pharmaceutical and biotechnology commercialization, I have found that successful organizations consistently follow the same fundamental principles.
02
Validate the Commercial Opportunity
Look beyond prevalence estimates. Evaluate how many patients are diagnosed, where they receive care, how they are referred, and how many are realistically accessible.
03
Understand the Decision Makers
Identify the physicians, Centers of Excellence, referral networks, advocacy organizations, caregivers, and healthcare systems that influence treatment decisions.
04
Evaluate the Competitive Landscape
Study existing therapies, emerging competitors, physician prescribing habits, clinical guidelines, and the factors that influence adoption of a new treatment.
05
Plan for Patient Access
Commercial success depends on more than regulatory approval. Reimbursement, specialty pharmacy, patient services, prior authorization, and distribution planning should begin well before launch.
06
Build the Right Organization
Every product requires a commercial organization designed around its specific market. Leadership, Medical Affairs, Market Access, Commercial Operations, Patient Services, and Sales must work toward a common strategy.
07
Execute with Excellence
Execution requires discipline, accountability, and alignment across the organization. A well-developed strategy only creates value when it is consistently executed.
08
Measure, Learn, and Adapt
Commercialization is an ongoing process. Organizations should continuously evaluate performance, respond to market changes, and refine strategy based on experience and real-world results.
Closing Perspective
Commercialization is not simply preparing for launch—it is building the foundation for long-term success.
Companies that consistently ask the right questions, challenge their assumptions, and execute with discipline place themselves in the strongest position to improve patient outcomes while creating sustainable shareholder value.
These eight principles have guided my approach to commercial strategy throughout my career and continue to serve as the foundation of the PharmaKonsult methodology.
About PharmaKonsult
PharmaKonsult provides strategic commercial advisory services to biotechnology companies preparing for commercialization, launching innovative therapies, or strengthening commercial performance.
Our work is centered on five core areas:
- Launch Excellence
- Commercial Strategy
- Commercial Leadership & Organizational Performance
- Neuroscience & Rare Disease Commercialization
- Endocrinology Commercialization
Every engagement is designed to help biotechnology companies make better commercial decisions—from early development through successful commercialization.